Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Mallinckrodt
Dow
Baxter
Moodys

Last Updated: January 27, 2023

Details for Patent: 7,815,942


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 7,815,942 protect, and when does it expire?

Patent 7,815,942 protects AZILECT and is included in one NDA.

This patent has twenty-six patent family members in eighteen countries.

Summary for Patent: 7,815,942
Title:Rasagiline formulations of improved content uniformity
Abstract:Disclosed are pharmaceutical preparations of R(+)-N-propargyl-1-aminoindan salts having enhanced content uniformity, processes for preparation of the compositions, and their uses.
Inventor(s): Peskin; Tirtza Berger (Raanana, IL)
Assignee: Teva Pharmaceutical Industries, Ltd. (Petach Tikva, IL)
Application Number:11/359,324
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form; Use; Process;

Drugs Protected by US Patent 7,815,942

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-001 May 16, 2006 AB RX Yes No See Plans and Pricing See Plans and Pricing Y Y TREATMENT OF PARKINSON'S DISEASE See Plans and Pricing
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-002 May 16, 2006 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y TREATMENT OF PARKINSON'S DISEASE See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,815,942

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006216696 See Plans and Pricing
Brazil PI0608209 See Plans and Pricing
Canada 2600011 See Plans and Pricing
Canada 2901244 See Plans and Pricing
China 101123946 See Plans and Pricing
European Patent Office 1848402 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Merck
Express Scripts
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.